News
Public · Published
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Alnylam Pharmaceuticals announced it will present new clinical and real-world data on AMVUTTRA (vutrisiran) at the AHA Scientific Sessions 2026 in Chicago and the ISA 2026 in Montevideo. Presentations include five-year HELIOS-B Phase 3 results, long-term cardiovascular outcomes, and insights on ATTR disease.
Published:
Updated:
What happened
Alnylam Pharmaceuticals announced it will present new clinical and real-world data on AMVUTTRA (vutrisiran) at the AHA Scientific Sessions 2026 in Chicago and the ISA 2026 in Montevideo. Presentations include five-year HELIOS-B Phase 3 results, long-term cardiovascular outcomes, and insights on ATTR disease.
Confirmed
Global impact / market context
Longer-term data from a landmark trial can strengthen confidence in AMVUTTRA's benefit for ATTR patients. If the five-year results confirm durable cardiovascular benefit, doctors may prescribe it earlier and more broadly, supporting Alnylam's revenue from this key RNAi therapy.
Analyst inference
Alnylam is the leading RNAi therapeutics company, and AMVUTTRA is central to its growth in ATTR amyloidosis, a progressive disease. Data presentations at major heart and amyloidosis meetings can shape physician adoption and competitive positioning, so investors watch whether the evidence broadens the drug's use.
Analyst inference
What to watch
- A late-breaking AHA presentation will report five-year HELIOS-B Phase 3 results, including two years of open-label extension data, giving the longest follow-up yet on vutrisiran's cardiovascular outcomes. Confirmed
- Watch whether Alnylam presents additional real-world evidence and earlier diagnosis or treatment insights at ISA 2026, which could support broader use of AMVUTTRA in ATTR care. Proposed
- Track whether the five-year data show sustained benefit on heart function and outcomes; weaker durability could pressure expectations for AMVUTTRA's long-term revenue, while stronger results may support wider prescribing. Analyst inference
Evidence
- Original source link unavailable